biostudies-literatureSaklatvala JRUK Medical Research Council Integrative Epidemiology UnitEstonian Research CouncilInnovative Medicines Initiative 2 Joint UndertakingNational Institute for Health Research (NIHR)NIHR Advanced FellowshipWellcome Trust14https://www.ebi.ac.uk/biostudies/studies/S-EPMC12857016biostudies-literatureUnknown18(1)<h4>Background</h4>Psoriasis is a common inflammatory skin disease with heterogeneous presentation. Up to 30% of individuals have severe disease with a greater surface area of skin involvement, co-morbidity burden and impact on quality of life. Prognostic biomarkers of psoriasis severity could improve allocation of clinical resources and enable earlier intervention to prevent disease progression, and a genetic biomarker would be cost-effective, stable over time, and unaffected by treatment or comorbidity.<h4>Methods</h4>Psoriasis severity was studied in four European population-based biobanks (Estonian Biobank, HUNT, FinnGen, UK Biobank) and classified based on level of clinical intervention received, with criteria for severe disease including hospitalisation due to psoriasis, use of systeGenome medicineGenetic liability to psoriasis predicts severe disease outcomes.PMC12857016PRG1911 and TK (TK214)220875/Z/20/ZMC_UU_00011/1, MC_UU_00032/01821511NIHR302258Helminen MTraks TEstrada KHarju TSmith CHObeidat MELoset MArvas MVlahiotis AGracia-Tabuenca JAddis LBowers NPerera GNgo DMakela TPMeretoja TBurova KMilani LXu FTsoi LCAberg FSuominen LDarne SSoininen HTuomi TBrumpton BMiller MLeinonen RMiller JSavukoski SRipatti SGkini MAUimari OKytola AHuertas-Vazquez AReilly DPiltonen TMcKenna KFarias FMishra RWong RHeikinheimo OPonnambath NLinna MMChung JHochfeld MTikkanen JKristiansson KWillberg TElenius KLoukola ABaudry Dde Rinaldis EPerola MReeve MPRemes AWaring JKoskelainen SRaghavan NLongerich SHassan SAarnisalo APalin KParkkinen JDuckworth MPalin HSagoo MKWeldatsadik RBetts JJacob HPelkonen MPaul DKulkarni DBizaki-Vallaskangas AFoerster JMagi RNiemi MMahil SKKahonen MBalasubramaniam PChen HTienari PVerdolini RUebe SAuvinen PKuopio THudjashov GFahy CTeng EKaarniranta KSimpson MAPlenge RLiu MBarton APylkas KJohnson SSliz EKlinger KSchutzman JSundararaj KO Donnell CDavitte JAnttonen VMurphy RWalton SGhazal AStrauss ESipila TPSaarentaus EAuro KGuan MPorello ALehto PLiu ASinisalo JMannermaa AJulkunen VKangasniemi EPunkka EFarkkila MLangan SMDymond HDaly MLemmela SCooper HLahesmaa RSistonen TBaxter KMars NLees TLaivuori HViollet CVaura FKingo KOwen CKalpala KMakela JRamessur RBonsall APartanen JLertratanakul ALaiho PLaukkanen MLaukkanen JOkafo GJussila ARunz HBrunfeldt MFranke ADesai TSerpi RNorris PKoks SOller DMaranville JMcDonough SJokimaa VLahtela LEKaunisto MJalanko AVaarasmaki MBarker JNRamo JNelis MPeltonen SHautalahti MAsvold BORenaud NTukiainen TAavikko MGulliver WIsometsa EBowes JSuvisaari JDada OAKankaanranta HVuoti SPikkarainen SRahimov FSalvary INititham JNiiranen TAittomaki KElliott APadmanabhuni SSEstonian Biobank research teamGordillo JERitari JAnstey ATaskinen MRVoutilainen MHiltunen TBruno SCostache MStefanescu SRiley-Gillis BAittokallio JZierer JDeGiovanni CHiltunen MEicher JKiiskinen TPetrovski SKauppi PTeder-Laving MKaukinen KAuranen ARamsay HLehtonen AChoy DLehisto ARahikkala EMorin-Papunen LMcCormack SLehtonen HWaterworth DSalmi TKaipiainen-Seppanen OKiviniemi MAntony FLyon CKoulu LGladman DDAli MRuddock MSmith SPalta PKallionpaa RPussinen PGarcia-Tabuenca JMattsson HLahteenmaki STaghipour KKaprio JBiswas SHu XPendergrass RSmaoui NJohn SBlomster TFinnGenTaylor MSaklatvala JRFerguson LVahatalo IToivola AWright AHart ABing NLaitinen TRodosthenous RRanasinghe AZiemann AEsko TKalliala IHammonds FKalavala MRotarescu RHe KJoensuu HReis ASiirtola HTachmazidou IMehtonen JTopliffe JOllila TKarihtala PWachsmuth RSipila KRiley-Gills BSalminen ETurunen JAGursoy UDonner KBewley AAugust SLabinoti LWiden ESchleutker JHiekkalinna TKettunen JGanna ASalminen AToppila-Salmi SGossel MOllila HSilven HKotaniemi-Talonen LElder JTPopovic RJarvensivu ETuovila OMantyla PTsuo KHedman AKilpelainen EGodwin AArcher CMellor SPaajanen THuffmeier UChen CYPujol NStuart PELayton AKoskela JLewis HHakanen AHavulinna ARaivio TSul JHTasanen KSiltanen SWahlfors TStrausz SRinne JRaivio MThomas LFValimaki NLoboda AVirolainen PRivas MTyrmi JMaasha MMannikko LSands KKolbinger FButt AUusitalo HTuoken HWilcox LMantere TPalomaki AKhorshid MWalsh SMetspalu AHovatta IWatts KKallio LHeyne HLessard SLuukkaala THinttala RLuo SMendelson MKivinen KTammerluoto JNair RPCaswell MPalotie ADand NFabre MBrown SJHuilaja LLaakkonen EAalto-Setala KMcCarthy MZheng ZPalotie UPalotie TDiba VMcCarthy LHernesniemi JAaltonen LAldoori NReeken SKanai MDavies EMattson JMakitie ARice DPirila LIsomaki PThomson MArffman RSalomaa VLee JParolo PDBShen HYSalo TChu APaternoster LLawson NLoomis SKurra VKilpi THuhtakangas JKhramtsova EKarjalainen MKarjalainen JZhou WEklund KMalarstig ACliff SChatelain CLevell NJung MNieminen PPitkanen EKosma VMPeltola JNiinimaki MHveem KLlorens VSoutherington TPopli UMetsarinne KWu YPitkanen NEaton SKurki MWade MWahie SLiao WHeikkinen SRahman PSinha TBSTOP study groupKhader SGraham RMouded MLu THannula-Jouppi KGordin DSiponen MJoseph TLahdenpera SCarpen OHyvarinen KLi QSDing ZLaisk TRose RKaiharju EKalviainen RRuotsalainen SEllinghaus DKajanne RMcBride SDomanne EKumar JBrown VDeSilva BChandran VfalseGenetic liability to psoriasis predicts severe disease outcomes.<h4>Background</h4>Psoriasis is a common inflammatory skin disease with heterogeneous presentation. Up to 30% of individuals have severe disease with a greater surface area of skin involvement, co-morbidity burden and impact on quality of life. Prognostic biomarkers of psoriasis severity could improve allocation of clinical resources and enable earlier intervention to prevent disease progression, and a genetic biomarker would be cost-effective, stable over time, and unaffected by treatment or comorbidity.<h4>Methods</h4>Psoriasis severity was studied in four European population-based biobanks (Estonian Biobank, HUNT, FinnGen, UK Biobank) and classified based on level of clinical intervention received, with criteria for severe disease including hospitalisation due to psoriasis, use of syste2025-01-01T00:00:00Z2025 Dec2026-06-14T06:09:11.86Z2026-06-14T03:15:04.849ZS-EPMC128570164140834910.1186/s13073-025-01561-2